Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

NovoCure (NASDAQ: NVCR) Board Vacancy Takes Effect September 2

NovoCure Ltd (NASDAQ: NVCR) lost Timothy Scannell from its Board effective September 2, 2026, when his seat was vacated under the company’s Articles of Association. The retirement was not attributed to any disagreement with NovoCure or its management.

Vinay Lochav | 10 September 2026

Novo Nordisk (NYSE: NVO) Treasury Shares Increase After Buybacks

Novo Nordisk’s repurchase programme accumulated 17,275,000 B shares worth DKK 5,221,774,293, while totalBuybackssince 4 February reached 32,034,179 shares worth DKK 9,021,774,283. The purchases left 46,074,876 B shares in treasury, equal to 1.0% of share capital.Key HighlightsNovo Nordisk repurchased 32,034,179 B shares since 4 February …

Vinay Lochav | 10 September 2026

Odyssey Therapeutics Outlines $433M Cash Runway Into H2 2028 (NASDAQ: ODTX)

Odyssey Therapeutics, Inc. (NASDAQ: ODTX) outlined a $433 million cash balance as of June 30 and said it expects the funds to support operations into H2 2028. The presentation also set out clinical milestones for its inflammatory and autoimmune disease programs.

Vinay Lochav | 10 September 2026

Omada Health President Forfeits 1,843 Shares at $22.77 (NASDAQ: OMDA)

Omada Health, Inc. (NASDAQ: OMDA) President Shao Wei-Li forfeited 1,843 shares at $22.77 per share, leaving 299,349 shares after the transaction. The transaction took place on September 5, 2026.

Vinay Lochav | 10 September 2026

Opus Genetics (NASDAQ: IRD) Expects 2027 Phase 3 Planning for OPGx-BEST1

Opus Genetics, Inc. (NASDAQ: IRD) is moving OPGx-BEST1 into higher-dose Cohort 2 at 4.5 x 10⁹ vg/eye after low-dose Cohort 1 produced clinically meaningful visual-function improvement in all five participants. The company said the early results also showed structural changes and a favorable safety …

Vinay Lochav | 10 September 2026

OS Therapies (AMEX: OSTX) Approves Restated Incentive Plan With 4.52M For Votes

OS Therapies Inc (AMEX: OSTX) secured approval for its amended and restated 2023 Incentive Compensation Plan with 4,515,930 votes in favor on September 9, 2026. Its stated purpose is to attract, motivate, retain and reward high-quality personnel while creating performance incentives tied toShareholdervalue.

Vinay Lochav | 10 September 2026

Merit Medical (NASDAQ: MMSI) Awards 8,371 Shares to Lewis Sheri

MERIT MEDICAL SYSTEMS INC (NASDAQ: MMSI) awarded Lewis Sheri 8,371 shares at $0 per share. Sheri is the company’s executive vice president of Global Operations.

Vinay Lochav | 10 September 2026

Nanobiotix (NASDAQ: NBTX) Investors Get September 15 Management Access

Nanobiotix S.A. (NASDAQ: NBTX) will participate in the H.C. Wainwright Annual Global Investment Conference on September 15, 2026. The company’s management will take part in a fireside chat, giving investors a scheduled opportunity to hear directly from its senior executives.

Vinay Lochav | 10 September 2026

Nano-X Imaging (NASDAQ: NNOX) Reports U.S. and Latin America Expansion Updates After Q2 Results

Nano-X Imaging Ltd. (NASDAQ: NNOX) reported an additional U.S. distribution agreement and a Costa Rica distribution agreement supporting continued expansion across Latin America while holding $31.023 million in cash at June 30, 2026. The balance stood at $49.151 million on December 31, 2025. The …

Vinay Lochav | 10 September 2026

National Vision (NASDAQ: EYE) CTO Exercises Options for 12,998 Shares

National Vision Holdings, Inc. (NASDAQ: EYE) Chief Technology Officer David Cutler exercised options covering 12,998 shares on Sep. 8, 2026. The transaction left him with 12,998 shares, representing about 100.0% of his resulting share holding.

Vinay Lochav | 10 September 2026
Support

Hi! How can we help you today?

Loading…